Across the country, hospital intensive care units admit more than 5 million critically ill patients. When these units are staffed by intensivists, lengths of stay and costs (estimated at $13 million annually) are reduced.

Although there are significant benefits to intensivist-led intervention and care, coverage continues to be an ongoing challenge, a challenge addressed by Avel eCare ICU. Utilizing innovative remote monitoring technology, Avel’s credentialed and privileged intensivists provide ongoing remote monitoring, immediate intervention, and on-demand consultation to help ICU teams respond faster when a critical change occurs.

Facilities with Avel eCare ICU services improve the use of evidence-based medicine, reduce staff burnout thanks to 24/7 monitoring, reduce rates of complications and mortality, and reduce transfers which deliver an economic boost to both the facility and the local community.

During the last 12 months, Avel eCare ICU has had the following impact:

• 203 lives saved
• $11.2 million in costs saved
• 7,000 less days on the ICU through faster response times to complications

INVU, Nuvo's FDA-approved remote patient monitoring platform, allows pregnant patients to conduct prenatal visits and fetal non-stress tests from the comfort of their own homes, without needing the assistance of a clinician to apply the device. Through a protocol driven prescription based service, patients and doctors may now enjoy greater connectivity and easier access to pregnancy monitoring. Patients and providers both experience immediate positive benefits, such as convenience, time saved, peace of mind and reduced costs of care.

INVU stands on the success of several pivotal trials, the results of which have been presented to the SMFM and published in the Gray Journal. We are laying the groundwork for collecting the largest high-resolution pregnancy data set in history, which we plan to use to develop advanced AI features. These will include predictive and prescriptive analytics, tools which can help predict high-risk complications such as preterm birth, as well as assist clinicians in building customized care plans based on patients’ needs.

Nuvo is an emerging leader in maternal-fetal connected health, passionate about creating technology that radically transforms the experience of pregnancy care for parents and healthcare providers. Our platform, INVU by Nuvo, is an innovative remote maternal-fetal monitoring solution that connects pregnant patients with a network of care, wherever they may be. INVU has been FDA approved for remote non-stress testing without the need for a clinician present to apply the device, and has recently been published in AJOG's prestigious Gray Journal .

Avel eCare ICU equips facilities with the support and expertise needed to achieve better outcomes for patients, improved ICU throughput and better support for staff. Avel eCare ICU can help:

• Improve the use of evidence-based medicine
• Increase confidence among patients and families with the high level of care available
• Offer 24/7 support for staff which reduces burnout, increases retention and improves recruitment
• Reduce ICU and hospital length of stay (LOS)
• Reduce rates of complications and mortality
• Reduce transfers, delivering an economic boost to your facility and community

NA at this time.

INVU stands head and shoulders above other remote pregnancy monitoring solutions for a number of reasons. We like to think of these through three distinct lenses as: Deep Data, Early Use, Accessed Anywhere.

Deep Data

• INVU's proprietary sensor band and accompanying cloud algorithms allow us to gain unprecedented insight in to the womb. Our collection of maternal and fetal data is achieved through a dual-modality of both ECG (biopotential) and PCG (sound) signals, all collected passively. This is unique in the field of pregnancy monitoring, and allows us to collect more reliable and robust signals than the standard of care today. Most of our competitors, on the other hand, utilize either unreliable and outdated legacy technologies such as doppler and toco, or EHG to obtain data.

Early Use

• INVU is FDA approved for antepartum use from gestational age 32 and onwards, with future FDA approvals intended to push this even earlier. By reaching patients in their third trimester, rather than when they reach the labor and delivery room, we enable greater insight into their health and trends. Our platform is designed to help doctors be proactive, rather than reactive.

Accessed Anywhere

• With the patient bearing the brunt of the care burden, especially when undergoing high-risk management, INVU was designed to be accessed by anyone, anywhere. As long as there is reliable internet access and a smartphone handy, the patient can undergo their monitoring session in comfort and with peace of mind. This significantly breaks down barriers of access to care, especially for underprivileged and rural patients.